Cargando…
BCG Therapy of Bladder Cancer Stimulates a Prolonged Release of the Chemoattractant CXCL10 (IP10) in Patient Urine
Background: Intra-vesical instillation of Bacille Calmette–Guérin (BCG), an attenuated strain of Mycobacterium bovis, is an effective therapy for high-grade non-muscle invasive bladder cancer (NMIBC), which provokes a local immune response resulting in 70% of patients free of relapse after three yea...
Autores principales: | Ashiru, Omodele, Esteso, Gloria, García‐Cuesta, Eva M., Castellano, Eva, Samba, Celia, Escudero-López, Eva, López‐Cobo, Sheila, Álvarez-Maestro, Mario, Linares, Ana, Ho, Mei M., Leibar, Asier, Martínez‐Piñeiro, Luis, Valés‐Gómez, Mar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678801/ https://www.ncbi.nlm.nih.gov/pubmed/31277459 http://dx.doi.org/10.3390/cancers11070940 |
Ejemplares similares
-
CyTOF analysis identifies unusual immune cells in urine of BCG-treated bladder cancer patients
por: Castellano, Eva, et al.
Publicado: (2022) -
NKG2D is a Key Receptor for Recognition of Bladder Cancer Cells by IL-2-Activated NK Cells and BCG Promotes NK Cell Activation
por: García-Cuesta, Eva María, et al.
Publicado: (2015) -
Natural Killer Anti-Tumor Activity Can Be Achieved by In Vitro Incubation With Heat-Killed BCG
por: Esteso, Gloria, et al.
Publicado: (2021) -
Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis
por: Rabquer, Bradley J, et al.
Publicado: (2011) -
An IP-10 (CXCL10)-Derived Peptide Inhibits Angiogenesis
por: Yates-Binder, Cecelia C., et al.
Publicado: (2012)